These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 38594129)

  • 21. Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years.
    Feld J; Belasen A; Navada SC
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):465-482. PubMed ID: 32479130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Zavras PD; Sinanidis I; Tsakiroglou P; Karantanos T
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
    Aul C; Giagounidis A; Germing U; Ganser A
    Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
    Pophali P; Desai SR; Shastri A
    Curr Hematol Malig Rep; 2023 Jun; 18(3):56-67. PubMed ID: 37052811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New investigational combinations for higher-risk MDS.
    Koenig KL; Borate U
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):368-374. PubMed ID: 36485141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myelodysplastic syndromes: Contemporary review and how we treat.
    Gangat N; Patnaik MM; Tefferi A
    Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes.
    Hasserjian RP; Buckstein R; Patnaik MM
    Am Soc Clin Oncol Educ Book; 2021 Mar; 41():328-350. PubMed ID: 34010050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
    Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
    BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
    Bataller A; Montalban-Bravo G; Bazinet A; Alvarado Y; Chien K; Venugopal S; Ishizawa J; Hammond D; Swaminathan M; Sasaki K; Issa GC; Short NJ; Masarova L; Daver NG; Kadia TM; Colla S; Qiao W; Huang X; Kanagal-Shamanna R; Hendrickson S; Ravandi F; Jabbour E; Kantarjian H; Garcia-Manero G
    Lancet Haematol; 2024 Mar; 11(3):e186-e195. PubMed ID: 38316133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Cogle CR; Scott BL; Boyd T; Garcia-Manero G
    Oncologist; 2015 Dec; 20(12):1404-12. PubMed ID: 26463870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes.
    Kota V; Ogbonnaya A; Farrelly E; Schroader BK; Raju A; Kristo F; Dalal M
    Future Oncol; 2022 Nov; 18(36):4017-4029. PubMed ID: 36622291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current and emerging strategies for management of myelodysplastic syndromes.
    Saygin C; Carraway HE
    Blood Rev; 2021 Jul; 48():100791. PubMed ID: 33423844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation.
    Rodriguez-Sevilla JJ; Adema V; Garcia-Manero G; Colla S
    Cell Rep Med; 2023 Feb; 4(2):100940. PubMed ID: 36787738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
    Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L
    Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis and classification of myelodysplastic syndromes.
    Hasserjian RP; Germing U; Malcovati L
    Blood; 2023 Dec; 142(26):2247-2257. PubMed ID: 37774372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of patients with lower-risk myelodysplastic syndromes.
    Brunner AM; Leitch HA; van de Loosdrecht AA; Bonadies N
    Blood Cancer J; 2022 Dec; 12(12):166. PubMed ID: 36517487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes.
    Sallman DA; Tanaka TN; List A; Bejar R
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):613-620. PubMed ID: 29025689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.
    DiGennaro J; Sallman DA
    Acta Haematol; 2024; 147(2):175-185. PubMed ID: 38052186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myelodysplastic syndromes: what do hospitalists need to know?
    Zeidan AM; Faltas B; Douglas Smith B; Gore S
    J Hosp Med; 2013 Jun; 8(6):351-7. PubMed ID: 23666619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
    Liu W; Zhou Z; Chen L; Wang X
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.